Abstract
In recent years, clinicians have sought a potent antiretroviral combination that can be administered once daily; the hope being that once-daily dosing would improve quality of life and adherence, thus increasing the likelihood of treatment success. Emtricitabine (FTC) is a very potent cytidine nucleoside analogue with a long plasma half-life. Based on the results of a small study, which showed that the combination of ddI + efavirenz + emtricitabine given once daily suppressed viral loads to <50 copies/mL in 93% of patients at 24 weeks, a larger international phase III trial (the FTC-301A Study) was designed. This manufacturer-sponsored trial used …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
